Literature DB >> 10647877

Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia.

M Bazzan1, G Tamponi, P Schinco, A Vaccarino, C Foli, G Gallone, A Pileri.   

Abstract

A total of 187 consecutive patients with essential thrombocythemia (ET) were diagnosed and followed by our Hematology Department in the period October 1980-November 1994. The overall follow-up was 773 patient-years. Thrombosis-free survival and overall survival were calculated for the whole cohort; the same parameters were then calculated after arbitrary division of the cohort into two groups, according to the median age at diagnosis (55 years). Fifty percent of the patients had at least one thrombotic episode within 9 years after diagnosis. The thrombosis-free survival curves calculated for patients younger or older than 55 years at diagnosis were comparable. About 85% of the patients were alive 10 years after diagnosis. The survival curves for patients younger and older than 55 years at diagnosis were not significantly different in the observation period, and the observed mortality (seven patients) among patients younger than 55 years at diagnosis was significantly higher than expected (1.68 cases). The relative risk of death was four times greater (SMR = 4.17, 95% C.I. 1.6-8.6, p<0.01) than for healthy, age-matched people living in the same area. Age at diagnosis, smoking, sex, hypercholesterolemia, peak number of platelets, hypertension, and diabetes were not significant prognostic cardiovascular risk factors in our cohort. In conclusion, our data show that ET has to be considered a serious disease that significantly decreases both quality of life (expected life without thrombosis) and life expectancy for younger patients.

Entities:  

Mesh:

Year:  1999        PMID: 10647877     DOI: 10.1007/s002770050555

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  11 in total

Review 1.  Cerebral sinus-venous thrombosis.

Authors:  Ida Martinelli; Serena Maria Passamonti; Elena Rossi; Valerio De Stefano
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

2.  Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.

Authors:  Malin Hultcrantz; Sigurdur Yngvi Kristinsson; Therese M-L Andersson; Ola Landgren; Sandra Eloranta; Asa Rangert Derolf; Paul W Dickman; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

3.  Coronary artery intervention after cytostatics treatment in unstable angina patient with essential thrombocythemia. A case report and literature review.

Authors:  Hyun Chang; Chi Young Shim; June-Won Cheong; Ju-Yeon Pyo; Young Guk Ko; Donghoon Choi; Yangsoo Jang
Journal:  Korean J Intern Med       Date:  2006-06       Impact factor: 2.884

4.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

5.  Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.

Authors:  A M Yesilova; S Yavuzer; H Yavuzer; M Cengiz; I D Toprak; E Hanedar; M C Ar; Z Baslar
Journal:  Int J Hematol       Date:  2016-10-03       Impact factor: 2.490

6.  JAK2V617F mutation in patients with splanchnic vein thrombosis.

Authors:  Sandra Guerra Xavier; Telma Gadelha; Glicínia Pimenta; Angela Maria Eugenio; Daniel Dias Ribeiro; Fernanda Mendes Gomes; Martin Bonamino; Ilana Renault Zalcberg; Nelson Spector
Journal:  Dig Dis Sci       Date:  2009-08-19       Impact factor: 3.199

Review 7.  Thrombocytosis: too much of a good thing?

Authors:  Andrew I Schafer
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

8.  Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.

Authors:  Jonathan S Bleeker; William J Hogan
Journal:  Thrombosis       Date:  2011-06-08

Review 9.  Essential thrombocythemia.

Authors:  Jean B Brière
Journal:  Orphanet J Rare Dis       Date:  2007-01-08       Impact factor: 4.123

10.  Reactive Thrombocytosis Associated with Acute Myocardial Infarction following STEMI with Percutaneous Coronary Intervention.

Authors:  Nat Dumrongmongcolgul; Charoen Mankongpaisarnrung; Grerk Sutamtewagul; Nattamol Hosiriluck; Timothy Chen; Alexander Trujillo; Nicholas Dcunha; Kenneth Nugent; Leigh Ann Jenkins
Journal:  Case Rep Cardiol       Date:  2013-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.